Men's Health News

RSS

Male circumcision shown to help prevent HIV transmission

According to a new study published in the Medical Journal of Australia, male circumcision can be seen as a “surgical vaccine” in the fight against heterosexual HIV transmission. The study based on spread of the virus in Africa showed that there was a reduced rate of transmission in regions where male circumcision was the norm.

19 Sep 2010

CBC members, patient advocacy organizations offer support for PRIME Act

In a presentation today at the Congressional Black Caucus Foundation's Annual Legislative Conference Health Braintrust meeting, Faina Shtern, M.D., president and CEO of AdMeTech Foundation, unveiled overwhelming support from Congressional Black Caucus members and patient advocacy organizations for the Prostate Research, Imaging, and Men's Education Act of 2010.

18 Sep 2010

PCF applauds new prostate cancer legislation

As hundreds of prostate cancer researchers, advocates and supporters Advance on Washington this week and push for more progress in fighting the disease, the Prostate Cancer Foundation applauds the prostate cancer legislation introduced on Tuesday by Senator Jon Tester of Montana.

17 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

CINJ experts available for discussion during National Prostate Cancer Awareness Month

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, treatments and prevention options surrounding prostate cancer during September, which is National Prostate Cancer Awareness Month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

Organizations issue five-point plan to accelerate research, discovery of effective prostate cancer treatments

With $3 billion spent on the over-treatment of prostate cancer each year, new discoveries are prompting the prostate cancer community to Advance on Washington the week of September 13 - 18. This initiative calls for renewed commitments to finding answers that will enable physicians to cure more and over-treat less. The nation's leading prostate cancer organizations today issued a five point plan, targeted to policymakers, to accelerate research and discovery of effective prostate cancer treatments.

15 Sep 2010

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

A recent TNS NIPO survey, on behalf of the Dutch Association of Urology (NVU) and the European Association of Urology (EAU), showed that almost four out of 10 Dutch men of 50 years and older suffer, or have suffered, from urinary complaints. The same number of men also said in the same survey they are worried that they may have prostate cancer.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Researchers develop new blood test to predict prostate cancer risk

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.

15 Sep 2010

Over half of men surveyed believe erectile dysfunction as a symptom of overall health

A new poll of men and women over 50 years old reveals that, while most men report some level of erectile dysfunction (ED), women generally aren't aware of the problem in their partners. The problem extends beyond simple communication since ED can often be a symptom of overall health and well-being in men.

14 Sep 2010

Differences between sexes affected by environment during first six months of life

It seems the old nature versus nurture debate can't be won. But a new Northwestern University study of men in the Philippines makes a strong case for nurture's role in male to female differences -- suggesting that rapid weight gain in the first six months of life predicts earlier puberty for boys.

14 Sep 2010

Less-invasive alternative to vasectomy

Pro-Vas® – the new faster, less-invasive alternative to traditional vasectomy – was featured Thursday in millions of homes and doctors' offices across the nation on "The Doctors" TV show. This nationally syndicated show highlights significant advancements in the world of health and medicine.

13 Sep 2010

Men with low PSA level does not benefit further treatment: Study

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.

13 Sep 2010

Measuring PSA levels effective in detecting prostate cancer: Study

A new multinational study suggests that regular blood testing to measure levels of prostate specific antigen (PSA) is more effective at detecting prostate cancer in men with a genetic predisposition to the disease.

13 Sep 2010

More men than women discontinue medications due to side effects

Men are more likely than women to discontinue a medication due to side effects. More and more men are diagnosed with age-related issues like enlarged prostate and men are being prescribed medications that have side effects. These side effects often cause men to say "NO." In the U.S. and Canada, Prostate prescriptions dominate the treatment of enlarged prostate.

10 Sep 2010

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.

10 Sep 2010

High testosterone levels in CEOs linked to higher rate of dropped deals in negotiating M&As

High testosterone levels in CEOs negotiating mergers and acquisitions are linked to a higher rate of dropped deals and an increase in hostile takeover attempts, according to a new study in the current issue of Management Science, a journal of the Institute for Operations Research and the Management Sciences (INFORMS-).

9 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

CyberKnife radiosurgery treatment effective for prostate cancer without side effects

CyberKnife radiosurgery treatment for prostate cancer is rapid, effective and has no side effects, with the added benefit of being non-invasive.

3 Sep 2010

Men's Health News

Male circumcision shown to help prevent HIV transmission

CBC members, patient advocacy organizations offer support for PRIME Act

PCF applauds new prostate cancer legislation

Johns Hopkins offers sources who can answer queries on prostrate cancer

CINJ experts available for discussion during National Prostate Cancer Awareness Month

Phase II clinical trial shows GTx-758 reduces serum free testosterone

Organizations issue five-point plan to accelerate research, discovery of effective prostate cancer treatments

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Researchers develop new blood test to predict prostate cancer risk

Over half of men surveyed believe erectile dysfunction as a symptom of overall health

Differences between sexes affected by environment during first six months of life

Less-invasive alternative to vasectomy

Men with low PSA level does not benefit further treatment: Study

Measuring PSA levels effective in detecting prostate cancer: Study

More men than women discontinue medications due to side effects

Experts advise men to maintain record of prostate specific antigen test results for risk detection

High testosterone levels in CEOs linked to higher rate of dropped deals in negotiating M&As

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CyberKnife radiosurgery treatment effective for prostate cancer without side effects

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News